Bristol Settlement Over Vanlev Could Require Clinical Trial Disclosure
This article was originally published in The Pink Sheet Daily
Proposed settlement would resolve class action suit alleging Bristol misled investors about safety problems with its failed investigational antihypertensive.
You may also be interested in...
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.